Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label, Dose-Optimization Phase II Clinical Trial to Evaluate the Efficacy and Safety of Single-Agent SMP-656 in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Progressed After Prior Treatment With HER2-Targeted Topoisomerase Inhibitor ADCs

NCT07726342 is registered in ClinicalTrials.gov with Chengdu SciMount Pharmatech Co., Ltd. as lead sponsor.

NCT NCT07726342
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07726342 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label, Dose-Optimization Phase II Clinical Trial to Evaluate the Efficacy and Safety of Single-Agent SMP-656 in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Progressed After Prior Treatment With HER2-Targeted Topoisomerase Inhibitor ADCs
Lead sponsor
Chengdu SciMount Pharmatech Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 16, 2026
Completion date
October 20, 2027
Enrollment
60 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer, locally advanced breast cancer (labc), metastatic breast cancer